Clinical Research: Phase 1 - Phase 4
Adaptive Design Methods Offer Rapid, Seamless Transition Between Study Phases in Rare Cancer Trials
Rare cancers account for 22 percent of cancer diagnoses worldwide, yet there is no universally accepted definition for a “rare” cancer. Moreover, with the evolution of genomics and associated changes in categorizing tumors, some common cancers are now characterized into groups of rare cancers, each with a unique implication for patient management and therapy. Adaptive...